Vol. XI, 1974

Seminars in HEMATOLOGY

Volume Contents

Contents

No. 1 (January)

LEUKEMIA AND LYMPHOMA. I

Introduction ..... *G. Hamilton Fairley* 1

Acute Leukemia in Adults..... *M. E. J. Beard and G. Hamilton Fairley* 5

Acute Lymphocytic Leukemia in Childhood..... *Joseph Simone* 25

Radiation Therapy of the Non-Hodgkin's Lymphomas .... *M. J. Peckham* 41

Chemotherapy of the Lymphomas..... *T. J. McElwain* 59

Preleukemic States ..... *Robert V. Pierre* 73

The Preleukemic Syndrome ..... *James W. Linman and Matti I. Saarni* 93

No. 2 (April)

LEUKEMIA AND LYMPHOMA. II

Current Concepts in Chronic Myelogenous Leukemia *P. A. Stryckmans* 101

Chronic Myelomonocytic Leukemia in Adults ..... *P. A. Miescher and J. J. Farquet* 129

Hematologic Malignancies and Other Marrow Failure States: Progress in the Management of Complicating Infections..... *Arthur S. Levine, Stephen C. Schimpff, Robert G. Graw, Jr., and Robert C. Young* 141

Chemotherapy After Synchronization of Tumor Cells ..... *H. O. Klein and K. J. Lennartz* 203

No. 3 (July)

HISTOCOMPATIBILITY, IMMUNOSUPPRESSION, AND BONE MARROW TRANSPLANTATION

Introduction ..... *Jon J. van Rood* 229

The HL-A System. I. Genetics and Molecular Biology ..... *R. Ceppellini and J. J. van Rood* 233

The HL-A System. II. Clinical Relevance ..... *J. J. van Rood* 253

Serologic Recognition of the Histocompatibility Antigens Using Agglutination and Cytotoxicity Techniques..... *J. W. Bruning* 263

Serologic Recognition of Histocompatibility Antigens Using Complement Fixation..... *J. Colombani and Monique Colombani* 273

Neutrophil-specific Antigens: Immunology and Clinical Significance *Parviz Lalezari and Eva Radel* 281

Immunogenetic Disparity and Graft-Versus-Host Reactions *Marilyn L. Bach and Fritz H. Bach* 291

The Cellular Recognition In Vitro of Antigens Related to Human Histocompatibility ..... *V. P. Eijsvoogel* 305

The Double Barrier in Bone Marrow Transplantation *D. W. van Bekkum* 325

Immunosuppression for Clinical Marrow Transplantation *George W. Santos* 341

Marrow Transplants in Aplastic Anemia and Leukemia ..... *A. Fefer, E. D. Thomas, C. D. Buckner, R. Storb, P. Neiman, H. Glucksberg, R. A. Clift, and K. G. Lerner* 353

Bone Marrow Transplantation in Children ..... *L. J. Dooren, R. P. Kamphuis, J. de Koning, and J. M. Vossen* 369

No. 4 (October)

HEMOGLOBINOPATHIES

Introduction . . . . . *Helen M. Ranney* 383

Human Hemoglobin Mutants With Abnormal Oxygen Binding
Ronald L. Nagel and Robert M. Bookchin 385

The Oxyhemoglobin Dissociation Curve and Pulmonary Gas Exchange
Peter D. Wagner 405

Human Hemoglobin Stability and Instability: Molecular Mechanisms and Some Clinical Correlations. . . . . *Ronald F. Rieder* 423

Denaturation of the Normal and Abnormal Hemoglobin Molecule
Eliezer A. Rachmilewitz 441

The Biosynthesis of Hemoglobin . . . . . *Edward J. Benz, Jr., and Bernard G. Forget* 463

Regulation of Fetal Hemoglobin Production . . . . *Haig H. Kazazian, Jr.* 525

Abnormal Globin Synthesis in Thalassemic Red Cells . . . *Elias Schwartz* 549

AUTHOR INDEX

Bach, F. H., 291
Bach, M. L., 291
Beard, M. E. J., 5
Benz, E. J., Jr., 463
Bookchin, R. M., 385, 577
Bruning, J. W., 263
Buckner, C. D., 353

Cartwright, G. E., 195
Ceppellini, R., 233
Cerami, A., 569
Clift, R. A., 353
Colombani, J., 273
Colombani, M., 273

de Koning, J., 369
Dooren, L. J., 369

Eijsvoogel, V. P., 305

Fairley, G. H., 1, 5
Farquet, J. J., 129
Fefer, A., 353
Forget, B. G., 463

Glucksberg, H., 353
Graw, R. G., Jr., 141

Kamphuis, R. P., 369
Kazazian, H. H., Jr., 525
Klein, H. O., 203

Lalezari, P., 281
Lennartz, K. J., 203
Lerner, K. G., 353
Levine, A. S., 141
Linman, J. W., 93

McElwain, T. J., 59
Miescher, P. A., 129

Nagel, R. L., 385, 577
Neiman, P., 353

Peckham, M. J., 41
Peterson, C. M., 569
Pierre, R. V., 73

Rachmilewitz, E. A., 441
Radel, E., 281
Ranney, H. M., 383
Rieder, R. F., 423

Saarni, M. I., 93
Santos, G. W., 341
Schimpff, S. C., 141
Schwartz, E., 549
Simone, J., 25
Storb, R., 353
Stryckmans, P. A., 101

Thomas, E. D., 353

van Bekkum, D. W., 325
van Rood, J. J., 229, 233, 253
Vossen, J. M., 369

Wagner, P. D., 405

Young, R. C., 141

SUBJECT INDEX

Amphotericin B, in treatment of fungal infections, 161–162
Anemia
  aplastic, 353–364
    graft-versus-host disease in, 357–358
    marrow transplants in, 353–364
    prognosis, 353–354
    therapy, 356–358
  Cooley's, 549–552
  Fanconi's, 75–76
  sickle cell, 577–592
  See also Sickling
Antibodies
  blocking, 276
  cellular recognition in vitro, 305–321
  family studies, 307–311
  genetics, 307–313
  HL-A, 285
  MLC activation, 307–311
  neutrophil-specific, 281–288
  See also Neutrophil-specific antigens

Bone marrow
  transplants, 325–338, 359–364, 369–380
    in adult lymphocytic leukemia, 363–364
    ALG, conditioning with, 332–333
    allogeneic, in acute leukemia, 361–363
    in aplastic anemia and leukemia, 353–364
    in children, 369–380
    cyclophosphamide, use of, 344–347
    cytostatic agents, 329–332
    double barrier in, 325–332
    graft take, factors influencing, 323–333
    graft-versus-host reaction, 325, 333–338, 349–350, 361–364
    See also graft-versus-host disease for hematologic malignancy, 359–361
    histocompatibility, role of, 354
    from identical twins, 355
    immunosuppression in, 341–354
    incompatibility between donor and recipient, 325–328
    irradiation, total body, 328–329, 342–344
    laminar downflow isolator for children, 372
Burkitt's lymphoma, 70
Busulfan, use in chronic myelogenous leukemia, 110–112

Cell-mediated lympholysis (CML)
  genetics of, 318–320
  histocompatibility, relation to, 320–321

Cell-mediated lympholysis (CML) (*Continued*)
HL-A and MLC, relation to, 320–321
kinetics, 320–321
reactivity, genetic control of, 297–301
test, 293
Complement fixation, 273–279
platelets, 274
techniques, 273
typing, 274–275
Cooley's anemia, 549–552
Cyclophosphamide, use in bone marrow transplants, 344–347
Cytosine, use in Burkitt's lymphoma, 70

DNA
functions in hemoglobin, 464–512
genetic code, structure of, 468
protein synthesis, general outline of, 466
transcription into messenger RNA, 467–468
See also RNA

EDTA microagglutination test, 270
Ehrlich ascites tumor investigation, 208–219
in animals, 208–213
in man, 213–219
proliferation, kinetics of, 206–207
synchronization, 207–208, 212–215

Graft-versus-host reaction. *See also* Bone marrow transplants
allograft phenomena in LD-different strains, 299–301
immunogenetic disparity and, 291–302
LD and SD differences in man, 297–299
SD-identical donors, problems of, 259
Granulocytopenia, 144

Heme iron, oxidation of, 442–443
Hemichromes
from oxidized subunits, denaturation of, 443–445
reversible and irreversible, 448–450
structural and functional properties, 445–450
Hemoglobin
assembly of, 490–492
B-chain variant, 540–541
denaturation of, abnormal heme and globin catabolism, 458–459
abnormal and unstable hemoglobins, 541–549
hemoglobin A induced by exogenous oxidants, 457–458
thriols, role of, 450–451
dissociation, heme–globin, 456–457
fetal
characteristics of, 525
disappearance, abnormal rates of, 534
distribution among erythrocytes, 525
etiology of, 537
γ-chain, structural heterogeneity in, 525–526
data on, 530–531
regulation of, 531–542
genetics of globin chains, 526–528
hereditary persistence of, 535
non-γ globin chains in human embryo, 529
in normal development, 532
production and regulation of, 525–542
formation of
hemichromes following oxidation of unstable hemoglobins, 454–456
hemoglobin tetramers, post-translational, 490–492
H-2 complex, detailed map of, 297
m-hemoglobins, 397–401
molecular mechanisms, 423–437
abnormal hemoglobins, structural alterations of, 433
α-helix, interference with conformation, 434
α-helix, structure of, 427
heme bindings, 427
heme group, attachment of, 432–433
heme, structure of, 424–425
primary structure, 424–425
quaternary structure, 430–432
tertiary structure, 428–430
mutants, human
with abnormal oxygen binding, 385–419
with high oxygen affinities, 388, 390–395
with low oxygen affinities, 395–397
SD and LD components of MHC, 301–302
synthesis, 463–512
H-2 complex. *See also* major histocompatibility complex
allograft response, phases of, 292–293
cellular models for study, 292–293
HL-A system
antibodies, 241–243
antigens
biology, molecular, 241–247
effect of dynamic state on lymphocyte membrane, 242
haplotypic combination, 237
molecule, description of, 241
recognition of, 263
resistance to lysis, 239
serotyping for LD polymorphism, 238–239
typing for MLC (LD) inhibition and immunofluorescence, 238

HL-A system (*Continued*)
grafting
homograft, reactions associated with, 253–259
HL-A7-negative recipients, skin graft survival in, 256
immunized recipients, importance of matching for SD, 256–257
LD-S interaction in vivo and allograft reaction, 257–258
matching for LD and SD and survival, kidney and skin, 255, 257–258
MLC reactivity and graft prognosis, 255
nonimmunized recipients, 254–256
immunization against, 260
serology, microtechniques in development of, 263
survival value of, 246–247
typing
antigen-antibody reactions, 264
discrepancies in typing same cells, 264
lymphocyte in serum, 266
methods of, 263
reagents, 265
sera, 264–266
Hodgkins disease, drugs and radiotherapy in, 59–61

Immune mechanisms, loss of in hematologic malignancies, 145
Immunosuppression, function of B and T cells in, 147
Infections in hematologic malignancies
anaerobic infections, treatment of, 157
bacterial infections, 154–156, 163
in bone marrow transplants, 176–178
causes, 142
cytomegalovirus, 171–172
diagnosis, 150–153
fatal, 142
fever of unknown origin, 153–155
fungal infections, reasons for increasing incidence, 157
aspergillosis, 158–159
candidiasis, 157–159
cryptococcosis, 160–161
histoplasmosis, 161
mucormycosis, 160
gram-negative sepsis, 150–151
herpes simplex, 168–170
incidence and etiology, 141–144
in leukemia and lymphoma, 142–143
mononucleosis, infectious, 170–171
Pneumocytis carinii, 163–165
predisposing factors, 144–148
prevention of, 148–150
Pseudomonas aeruginosa vaccine, 179
toxoplasmosis, 163–165
therapy of established infection, experimental approaches, 182–184
filtration leukapheresis in, 182–183
leukocyte transfusions, 182–183
vaccinia, 172–173
varicella-zoster, 166–168
viral infections, 165–166, 173–176
Isoimmune neonatal neutropenia, 284–285

Leukemia
acute lymphocytic, in childhood, 26–37
patients, selection of, 26
prognosis, 25, 37
remission, induction of, 28–29
myelogenous, chronic, 101–121
central nervous system, complications in, 19–21
chemotherapy, contraindications, 9–10
combination therapy, toxicity, 36
cytochemical stains in, 5–9
diagnosis of, 5–9
heparin, use of, 18
maintenance, 15
marrow hyperplasia, 11
platelet transfusion, 18
relapse, treatment of, 16
remission, indications, 10
supportive care, 16
myelogenous, chronic, 101–121
BCG and allogenic cultured cells, vaccination with, 119
blastic transformation, 107–110
busulfan, use of, 110–112
chemotherapy, use with, 106–107
dibromomannitol in, 112–113
hydroxyurea in, 113–114
irradiation to blood, 115–116
irradiation to spleen, 114–115
leukopheresis, failure of, 116
myelopoiesis, 101–102
origin, possible, 108
prognosis, 101
proliferation of myeloid cells, 105–107
polymorphonuclear cells, 102–103
splenectomy, 116–118
treatment of blastic transformation, 118–119
myelomonocytic, chronic in adults, 129–138
autopsy findings, 136
blood, peripheral, in, 133
bone marrow, condition of, 134–135
diagnosis, differential, 137
enzymatic erythrocyte activities (Geneva series), 135
laboratory findings, 133–134
lysozyme elevated in, 134
prognosis and treatment, 135–136

Leukemia (*Continued*)
symptoms and signs, clinical, at diagnosis, 133–138
Leukocytes
agglutination test, 269–270
antigens
capillary agglutination, 282–283
classification of, 281
medium, cell preparation for incubation, 282–283
methodology, 281–283
microagglutination test, 282
neutrophil, gene frequencies of, 281
mixed leukocyte culture test (MLC), 293
genetic control of reactivity, 293–297
reactivity and death, correlation between, 300
neutrophils
neonatal neutropenia, 284
specificity, methods for demonstrating, 283
Lymphocytes, mixed culture reactions. *See also* HL-A system
alleles, identification of, 236
complement fixation, results and validity, 276–278
histocompatibility, relation to, 315–317
HL-A matching and graft survival, correlation to MLC, 317
polymorphism, 236
reactivity, 306–307, 316–317
typing, 308–312
determinants, 313–315
homozygote cells used for, 313–314
serology, 237, 314, 315
Lymphocytoxicity, 268–269, 293
Lymphomas
childhood, treatment and survival in rats, 50–51
chemotherapy of, 59, 61–65, 203–204, 221
dose-time relationship in malignancy, 51–52
gastrointestinal malignant lymphomas, 49
generalized lymphocytic lymphoma, total body irradiation for, 53–56
head and neck, 47
non-Hodgkins lymphomas
chemotherapy of, 65–70
extranodal presentations, 45
localized presentations, 41
radiation therapy, 41–56
survival data, 46
staging in, 53
Waldeyer's ring, 48–50
Lymphosarcoma
childhood, symptoms and treatment of, 70
chemotherapy, 67–69
regressions, 69

Marrow. *See* bone marrow
Major histocompatibility complex (MHC). *See also* HL-A system
Methotrexate, use in Burkitt's lymphoma, 70
Mixed lymphocyte culture reaction. *See also* lymphocytes
MOPP combination chemotherapy, 61–62
MUPP, compared with MOPP, 62–63

Neutropenia, neonatal, 284–285
Neutrophil
function, impairment of, 145
incompatibility, transfusion reactions, 286–287
Neutrophil-specific antigens, immunology and clinical significance, 281–288

Oxyhemoglobin dissociation curve and pulmonary gas exchange, 405–419
diffusion of, 415–419
lung as a whole organ, 412–415

Philadelphia chromosome, 103–104, 120–121
in clonal origin of CML, 120–121
Polymorphonuclear cells, functional capacity, 103
Polyribosome, function and analysis, 489–490
Preleukemic states, 73–86, 93–98
chromosome analysis in diagnosis, 79–86
studies in control subjects, 81
bone marrow studies, serial, 83
definition, 73
diagnosis, 73
disorders, potentially leukemic, 75
ataxia telangiectasa, 76
Bloom's syndrome, 76
Fanconi's anemia, 75–76
Kostmann's disease, 76
radiation exposure, 76
drug or chemical exposure
benzene, 76
chloramphenicol, 77
phenylbutazone, 77
hematologic changes, 76–79
abnormalities, predominant, 94–97
anemia
acute nonlymphocytic, 82–83
aplastic, 77
macrocytic, 79
refractory sideroblastic, 78
aplasia, pure red cell, 78
monocytosis, 79
neutropenia, 78
thrombocytopenia, 78

Reticulum cell sarcoma, 216
Ribosomes
  recycling of, 487–489
  reticulocyte, specificity, 498
RNA
  functions in hemoglobin, 464–512
  globin messenger
    biosynthesis of, 471–472
    characteristics of, 468–469
    in cytoplasm, processing of, 474–475
    translation of, 475–476
    gene expression, control of, 475–476
    poly (A) sequences in, 470
    transport from nucleus to cytoplasm, 472
    untranslated sequences of, 470–471
  messenger
    codons for amino acids, 469
    hemin, effect on initiation, 500–502
    initiation factors, specific, 498–500
    molecular structure of, 473
    nuclear events, synthesis and processing, 467–468
    protein synthesis, general outline of, 466
    transcription of DNA into, 467–468

Sarcoma
  reticulum cell, 216
  Sternberg's syndrome, anemia associated with, 70
Sickle cell disease, 569–592
  2-3-diphosphoglycerate, effect of, 487–488
  deoxygenation, role of, 587
  hemoglobin
    carbamylation of, 571–572
    heterozygotes, double, of hemoglobin, and interactions between, 577–592
    intracellular, importance of concentration, 588
    molecules, factors affecting interaction between, 577–588
    sickling syndromes, relative clinical severity of, 489
  hemoglobin C, 588–589
  hemoglobin F, role of, proportion and distribution, 592
  hemoglobin S, 578–592
  heterozygotes, double, and structural chain mutants, 590–591
  homozygous, with structure of chain mutants, 591
  mutations
    combinations with other "insoluble" mutants, 586
    gelation with other structural mutants, 584
    intermolecular contacts, nature of, 587
    observations and description, 578–579
    polymer, structure of, 579–583
    α-thalassemia, combinations with, 592
  therapy, with sodium cyanate, 569–575
    animal studies, 570–575
    antisickling action, mechanism of, 569–570
    cyanate's effect on blood oxygen, 570
    history of cyanate as antisickling agent, 569
    specificity and mechanism of cyanate, 569–570

Thalassemia syndrome, 451–452, 504–506, 549–564
  α-thalassemia, 562–564
    description and symptoms, 562–563
  β-thalassemia, 552–562
    globin synthesis in, 554, 556, 558
    heterozygous, 555–562
    homozygous, 552–555
  Cooley's anemia, 549–552
  hemoglobin H (HbH) disease, 549–552
  mRNA, deficiency in, 504–505
  nonthalassemic states and abnormal synthesis of structurally normal globin chains, 506–507

X-ray therapy, negative effects in hematologic malignancies, 146